AstraZeneca to reportedly resume its COVID-19 vaccine trial in the US
Category: #health  By Saipriya Iyer  Date: 2020-10-22
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

AstraZeneca to reportedly resume its COVID-19 vaccine trial in the US

After the events that transpired on September 6, AstraZeneca has finally received a nod from the US regulator- FDA- to resume its COVID-19 vaccine trial in the country. The FDA came to this decision after conducting a detailed review on after a study participant experienced serious illness.

Reportedly, a participant from AstraZeneca's UK trial suffered from the illness, which some investigators suspect to be a rare spinal inflammatory disease known as transverse myelitis.

According to reliable sources, the US trial could be back up and running by this week. The regulators were unclear on the characterization of the illness. As a result, the FDA instructed researchers performing the trial to give more details of the incident on consent forms which then would be signed by study participants.

As for the UK’s regulatory board, the agency was unable to conclude whether the incident was related to the vaccine because of insufficient evidence. Moreover, a group of independent reviewers along with MHRA (Medicines and Healthcare products Regulatory Agency) suggested that the vaccinations should continue.

Nevertheless, close monitoring of all the participants and affected individuals will be continued. Regulators from countries like India, South Africa and Brazil have also allowed AstraZeneca to continue its vaccine trials.

However, in a recent event, the Brazilian health authority Anvisa reported the death of a volunteer from the company’s COVID-19 clinical trial, stating to have received data on this matter from an investigation.

The Federal University of Sao Paulo, the place that was coordinating phase 3 clinical trials in Brazil, did confirm the volunteer to be a Brazilian but did not provide any personal information like address or city.

The results of this news were visible on AstraZeneca’s share price, which turned negative and recorded a 1.7% decline. The Brazilian government intends to buy the UK vaccine and manufacture it at FioCruz in Rio de Janeiro.

 

Source Credit: https://www.moneycontrol.com/news/trends/health-trends/astrazeneca-us-covid-19-vaccine-trial-may-resume-as-soon-as-this-week-5990311.html



About Author

Saipriya Iyer

Email: [email protected]   linkdin twitter

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

More News By Saipriya Iyer

 Tabletop Tape Dispensers  market valuation to surge at healthy CAGR through 2026

Tabletop Tape Dispensers market valuation to surge at healthy CAGR through 2026

By Saipriya Iyer

A comprehensive research study on Tabletop Tape Dispensers market added by Market Study Report provides insights into the market size and growth trends of this industry over the forecast timeline. The study evaluates key aspects of Tabletop Tape D...

APAC, Europe, America region to generate massive revenues for General Well-Being Dietary Supplements market by 2026

APAC, Europe, America region to generate massive revenues for General Well-Being Dietary Supplements market by 2026

By Saipriya Iyer

MarketStudyReport.com presents latest report on global General Well-Being Dietary Supplements Market, which evaluates the growth trends of the industry through historical study and estimates future prospects based on comprehensive research. The re...

Eugenia Jambolana Extract Market to Increase Exponentially During 2027

Eugenia Jambolana Extract Market to Increase Exponentially During 2027

By Saipriya Iyer

The report Eugenia Jambolana Extract market provides high-quality information regarding the major market trends, product types and their application scope, competitive landscape, and impact of COVID-19 outbreak.

.

Request a...